Abstract

GLIMPSES ON COVID-19 AND 2-DEOXY D-GLUCOSE AS A NOVEL APPROACH IN EMERGENCY TREATMENT: A REVIEW

Jerin James* and Soji S.

Abstract

Covid 19 is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2. It destructively spread all over the world. COVID-19 was identified in Wuhan City of China, on December 12th, 2019. Dr. Tedros Adhanom Ghebreyesus declared that the infection developed due to severe acute respiratory syndrome coronavirus 2 is “COVID-19” on February 11th, 2020. From the beginning, most treatment strategies were focused on symptomatic management and supportive therapy only. But now vaccines are also available. Recently, for emergency purposes, India's drug controller general has authorized “2-Deoxy-D-glucose” as an adjunct treatment. This review aims to provide some information about recently introduced 2-deoxy D-glucose. The lack of hydroxyl group at the second position makes this drug differ from glucose. It inhibits the living cell's glycolysis pathway and contains viral replication. As per the phase II clinical trial, it showed a positive outcome and reduced oxygen dependence. Now phase III is going on several hospitals across India. But studies showed some adverse effects also.

Keywords: Covid-19, 2-Deoxy-D-glucose, Glycolysis, Clinical trial, Adverse effect.